We use cookies and tracking technologies to offer you a better browsing experience, analyze site traffic, and improve the website. By clicking “Accept Cookies”, you expressly agree to our use of cookies and tracking technologies in accordance with our Cookie Policy. If you wish to prevent your data from being used by Google Analytics you can opt-out below.
Google Analytics Opt-Out

December 10, 2023

Cencora's Brian Biehn Forecasts Big Changes for the US Biosimilar Space

Brian Biehn, Senior Director of Biosimilar Commercialization at Cencora, formerly known as AmerisourceBergen, recaps some of the major regulatory updates for biosimilars in the United States and makes predictions for how the market will develop in the years to come.
Read press release

More in the Media

Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD

September 28, 2022

Outsourcing Pharma

Recruitment tool pairs pharma firms with providers to boost patient connection 

July 18, 2022

Pharmaceutical Executive

Physician Practices Post-Pandemic: Q&A with AmerisourceBergen Leadership

July 06, 2021

AmerisourceBergen Commends the Introduction of S. 1909 & H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act, in Congress

June 08, 2021

800.543.2111

  • Terms and Conditions
  • Data Subject Request
  • Privacy
  • LinkedIn
  • X
  • Facebook
Contact Us
Cencora logo

brand="Cencora" culture="EN" env="Development" tracker="False"